November 2, 2012 / 10:24 AM / 5 years ago

Valeant profit slides, cuts fourth-quarter profit outlook

(Reuters) - Valeant Pharmaceuticals International Inc VRX.TO VRX.N, Canada’s biggest public drugmaker, reported an 81 percent drop in third-quarter profit, and the company cut its profit forecast for the current quarter.

Net income fell to $7.6 million, or 2 cents per share, from $40.9 million, or 13 cents per share, a year earlier.

Total revenue rose 47 percent to $884.1 million. (Reporting by Bhaswati Mukhopadhyay in Bangalore and Allison Martell in Toronto; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below